Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

NCT ID: NCT00289341

Last Updated: 2013-01-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-03-31
• Study Completion Date: 2008-11-30

Brief Summary

The purpose of this study is to assess the safety and activity of a type of vaccine as immune therapy for prostate cancer. This vaccine will be made for each participant's own immune cells (called dendritic cells) obtained by blood donation. Dendritic cells are immune cells, whose role is to identify foreign antigens (bacteria, viruses, or tumor cells, for example) in the body and to activate other cells of the immune system to mount an attack on that foreign antigen. Each participant will be randomized into either Arm 1 (experimental treatment only) or Arm 2 (placebo first, then the experimental treatment). Participants will be given the vaccine and three boosters as an injection. After the placebo phase, each participant in Arm 2 will crossover to the treatment phase so that all participants will eventually receive the experimental treatment.

Detailed Description

This is a Phase I/II dendritic cell vaccine study for patients with prostate cancer. Our laboratory has demonstrated that effective tumor immunity in humans is associated with, and likely mediated at least in part by tumor antigen-specific killer T cells (Albert et al., 1998a; Darnell, 1999; Darnell and Posner, 2003). Moreover, we have demonstrated that apoptotic material derived from dying tumor cells are a potent means of delivering antigen to DCs and subsequently triggering tumor antigen-specific T cell responses ex vivo (Albert et al., 1998a; Albert et al., 1998c). In this study, patients with 3 consecutive rises in PSA measured at least 2 week apart, after definite local therapy (prostatectomy or radiation) will be recruited. Peripheral blood monocytes will be collected by leukapheresis and dendritic cells will be generated in the Cleanroom in the Laboratory of Molecular Neuro-Oncology. These dendritic cells will be pulsed with apoptotic prostate cancer cells from a cell line (LNCaP), harvested, tested for certain release criteria, and then injected as vaccine. When patients are found to be eligible for the study, they will be randomized into either the experimental group or the placebo group for the purposes of comparing adverse events between groups only. Vaccine plus 3 boosters (or placebo) will be given, each two weeks apart. After the third booster, patients will be unblinded. Those receiving the vaccine will when enter the follow up phase which includes a post treatment leukapheresis. Those in the placebo group will cross over and receive the vaccine and boosters. The primary outcomes to be evaluated are toxicity and activity. Patients will be evaluated for both local and systemic toxicity. For activity, we measure both immunological and clinical responses to the vaccine, comparing measures taken before and after vaccination, combining patients in both arms.

Conditions

Prostate Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Placebo

12 patients in the placebo Arm for 8 weeks followed by DC/LNCAP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks.

Group Type: PLACEBO_COMPARATOR

vaccine vehicle only

Intervention Type: BIOLOGICAL

Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.

DC/LNCaP

12 patients, receiving DC/LNCaP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks

Group Type: EXPERIMENTAL

DC/LNCaP

Intervention Type: BIOLOGICAL

Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH

Interventions

vaccine vehicle only

Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.

Intervention Type: BIOLOGICAL

DC/LNCaP

Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Disease Characteristics

• Histologically confirmed prostate carcinoma
• Progressive, disease required, i.e.: elevated PSA documented to be rising on 3 occasions, either despite castrate testosterone levels (below 50 ng/dl), or after definitive local therapy (prostatectomy or radiation).

Prior/Concurrent Therapy

-Biologic therapy:

• Recovered from toxicity of any prior therapy

-Chemotherapy:

• At least 4 weeks since chemotherapy -Endocrine evaluation/therapy
• 3 rising PSA values at least 2 weeks apart
• At least 2 weeks since concurrent corticosteroids (other than for replacement therapy for adrenal insufficiency)
• Medical hormonal therapy to maintain castrate testosterone levels permitted

-Radiotherapy:

• At least 4 weeks since radiotherapy

-Surgery:

• Prior surgery allowed

Patient Characteristics

• Age: 18 and over, able to give written informed consent. Individuals unable to provide informed consent must have consent provided by the legal guardian, or person designated by the subject to give consent on his behalf.
• Performance status: Karnofsky 70-100%
• Life expectancy: At least 1 year
• Hematopoietic: obtained twice, once within 45 days prior to study entry, and again within 72 hours of study entry.
• WBC greater than 3,800
• Absolute neutrophils greater than 1,500
• Absolute lymphocytes greater than 500
• Platelets greater than 120,000
• Hb at least 10 g/dl
• Hepatic:

--Bilirubin less than 2.0 mg/dl OR

--SGOT less than 2 x ULN

• Renal:

• Creatinine no greater than 2.0 mg/dl OR
• Creatinine clearance at least 40 ml/min
• Rheumatologic:

--ANA no greater than upper limit of normal, or ANA abnormal in absence of clinical signs of autoimmunity.

• Rheumatoid factor (RF) no greater than upper limit of normal, or RF abnormal in absence of clinical signs of autoimmunity.
• Anti-ds DNA no greater than upper limit of normal, or anti ds DNA abnormal in absence of clinical signs of autoimmunity.
• Immunologic:
• Influenza serology (assessment made at time of screening).
• Assessment of DTH response to a standard anergy panel (to include candida, trichophyton and tetanus) or to a Multitest CMI (a disposable kit for DTH testing with standardized preloaded antigens).
• Endocrine:

--TSH, T3, and T4 no greater than upper limit of normal

• Radiographic:

• Baseline bone scan
• Baseline CT or MRI of abdomen and pelvis

Exclusion Criteria

Disease Characteristics -No active CNS metastases

Prior/Concurrent Therapy

• Biologic therapy:

• No prior autologous or allogeneic tumor vaccines
• No concurrent other immunotherapy
• Chemotherapy

--Not previously treated with more than 2 chemotherapy regimens

• No concurrent chemotherapy
• Radiotherapy --No concurrent radiotherapy

Patient Characteristics -Cardiovascular: No NYHA class III/IV status No active angina, clinically significant cardiac arrythmia, recent (6 months) myocardial infarction

• Pulmonary:

--No severe debilitating pulmonary disease

• Other:

• No active infection requiring antibiotics
• No active pain requiring chronic opioid analgesics.
• Not HIV, hepatitis B or hepatitis C virus positive; anti-HIV, HbsAg and Hep C antibody negative
• No history of hypersensitivity to vaccine components
• No serious uncontrolled medical illness
• No currently active second malignancy other than non-melanoma skin cancer (note: a patient is NOT considered to have currently active malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse)
• No history of total lymph node irradiation
• No history of vasculitis, including but not limited to systemic necrotizing vasculitides (polyarteritis nodosa group), hypersensitivity vasculitis, Wegener's granulomatosis.
• No history of autoimmune disease.
• No use of hydroxyurea within 45 days of study entry
• No receipt of immune modulators or suppressors within 30 days prior to study entry, including but not limited to interferons and thalidomide. No active requirement for corticosteroids; prior use is acceptable.
• No psychiatric illness or social condition that, in the opinion of the investigator, would interfere with adherence to study requirements.
• No alcohol or drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Rockefeller University

OTHER

Sponsor Role: lead

Responsible Party

Robert Darnell

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Robert B. Darnell, MD, PHD

Role: PRINCIPAL_INVESTIGATOR

Rockefeller University

Locations

Rockefeller University Hospital

New York, New York, United States

Countries

United States

References

Frank MO, Kaufman J, Parveen S, Blachere NE, Orange DE, Darnell RB. Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer. J Transl Med. 2014 Dec 5;12:338. doi: 10.1186/s12967-014-0338-3.

Reference Type: DERIVED

PMID: 25475068 (View on PubMed)

Frank MO, Kaufman J, Tian S, Suarez-Farinas M, Parveen S, Blachere NE, Morris MJ, Slovin S, Scher HI, Albert ML, Darnell RB. Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PLoS One. 2010 Sep 1;5(9):e12367. doi: 10.1371/journal.pone.0012367.

Reference Type: DERIVED

PMID: 20824184 (View on PubMed)

Other Identifiers

RDA 0466

Identifier Type: -

Identifier Source: org_study_id